Background--We developed risk models for predicting acute kidney injury (AKI) and AKI requiring dialysis (AKI-D) after percutaneous coronary intervention (PCI) to support quality assessment and the use of preventative strategies.
A cute kidney injury (AKI) is a serious complication of PCI and is associated with an increased risk of myocardial infarction, dialysis and death. [1] [2] [3] [4] [5] It is common, with a reported incidence after PCI of between 3% and 19% and can be mitigated by the use of hydration and the avoidance of excess contrast. [6] [7] [8] [9] It is also associated with a number of preprocedural clinical factors such as pre-existing chronic kidney disease that make it an ideal target for risk modeling.
However, previous models of AKI were developed over 10 years ago, prior to the contemporary use of hydration protocols and low-osmolar contrast agents, and were not based on the Acute Kidney Injury Network (AKIN) criteria, which has become the contemporary consensus criteria for defining AKI. 2, 5, 10 Moreover, the importance of such a model has expanded in the current era, where there is a growing focus on safety, quality improvement, patient-centered care, and personalized medicine.
11,12
With respect to quality assessment and improvement, the American College of Cardiology (ACC) sought to provide risk-adjusted AKI rates to hospitals participating in its National Cardiovascular Data Registry (NCDR) so that comparative benchmarking and quality improvement could occur. Moreover, by prospectively knowing the AKI risk of an individual patient, it would also be possible to tailor treatment (eg, use of hydration protocols, low-osmolar contrast agents, staging of multi-vessel PCI procedures for patient safety reasons to minimize acute contrast exposure, etc.) to maximize safety and outcomes. Riskadjusted models of other outcomes are increasingly being used to facilitate medical decision making, 13 personalize informed consent documents, 14 and support quality improvement efforts 15 and have been used in to improve patients' engagement and understanding of the risks and benefits of PCI. [16] [17] [18] [19] Accordingly, we used the ACC NCDR to develop and validate a parsimonious risk model for AKI and AKI requiring dialysis (AKI-D) to support more accurate informed consent, safer care, and quality improvement.
Methods

Study Population
The NCDR Cath-PCI registry, co-sponsored by the ACC and the Society for Cardiovascular Angiography and Interventions, has been previously described. 20, 21 The registry catalogs data on patient and hospital characteristics, clinical presentation, treatments, and outcomes associated with PCI from >1000 sites across the United States. The data are entered into ACC-certified software at participating institutions. There is a comprehensive data quality program, including both data quality report specifications for data capture and transmission and an auditing program. 22 The data collected are exported in a standard format to the ACC Heart House (Washington, DC). Complete definitions of all variables were prospectively defined by an ACC committee and are available at the ACC NCDR web site (http://www.acc.org/ncdr/ cathlab.htm).
For this study, we identified all patients receiving PCI between June 1, 2009 and June 30, 2011 enrolled in the NCDR CathPCI Registry (N=1 254 089). We excluded patients discharged on the day of their procedure (n=42 029; 3.4%), without a pre-and post-procedure serum creatinine (n=207 789; 16.6%), patients undergoing multiple PCI's during a single hospitalization (n=32 999; 2.6%), and patients currently on dialysis at the time of their PCI (n=24 517; 2.0%). The final analytic cohort included 947 012 patients receiving PCI that were randomly divided into a 70% derivation (n=662 504) and 30% validation cohort (n=284 508; Figure 1 ). A comparison of those with and without creatinine levels before or after their procedure with those included in the cohort revealed minimal differences (results available from authors upon request).
Study Outcomes and Variables
The primary outcome was AKI, using the change from preprocedure to peak serum creatinine after the procedure. We used the contemporary standardized definition for AKI as described by the Acute Kidney Injury Network for Stage 1 or greater injury, which is defined as a ≥0.3 mg/dL absolute or ≥1.5-fold relative increase in post-PCI creatinine or new initiation of dialysis. 23 As urine output is not collected within the NCDR registry, this facet of the definition was omitted, which may have led to some patients developing a reduction in urine output without a rise in their creatinine being misclassified as not having AKI. AKI requiring dialysis (AKI-D) was identified using a pre-defined NCDR data element for acute or worsening renal failure necessitating new renal dialysis by the participating centers. Patients with AKI-D were included in the AKI group but were also examined separately, given its clinical importance, to identify independent predictors for requiring dialysis after PCI.
Framing of the Analysis
The purpose of risk-adjustment to support quality assessment/improvement or tailored approaches to treatment is to account for patient characteristics prior to the initiation of treatment. 24 We therefore considered potential predictor variables to be those that existed prior to the initiation of PCI. Although contrast is clearly known to be associated with the development of AKI and AKI-D, it was not considered as a potential predictor as the amount of contrast needed is not known at the start of PCI, varies substantially by operator and hospital, and may mask differences in the safety of PCI across centers if it were accounted for in the risk model.
Data Analysis
Data are described as proportions or meanAESD. Baseline patient characteristics and variables with clinical or statistically significant associations with both AKI and AKI-D were included To create a more parsimonious, practical model for clinical use, variables were ranked by the strength of their association with AKI and sequentially removed until the adjusted R 2 of the logistic regression model reached 95% of the full model. 25 The loss of discriminatory power with the reduced model was compared with the full model using the computed integrated discrimination improvement (IDI) 26 and the difference in c-statistics. To further support prospective clinical use of the model, we created a simple integer-scoring model by assigning a weighted integer coefficient value corresponding to each variable's b-weight for the prediction of both AKI and AKI-D. 27 Finally, model calibration and discrimination for both the full and integer models of AKI and AKI-D were evaluated in the 30% validation sample using the c-statistics and the slope of the predicted versus observed rates of AKI/Dialysis within deciles of predicted AKI/Dialysis risk. SAS (version 9.2; SAS Institute, Cary, NC) statistical software was used for all statistical testing.
Sensitivity Analysis
To address whether a single model can adequately risk stratify patients with distinctly different clinical settings, we tested a number of interaction terms including, STEMI, NSTEMI, and baseline CKD and a spline term for age. None of the interaction terms were significant suggesting the model performed well in those patient subsets and arguing against separate models. Observed versus expected plots for the clinically important subsets of patients with severe CKD, STEMI, NSTEMI, and Non-ACS were also examined and the cstatistics and calibration slope of the model within each subgroup assessed.
Results
Baseline characteristics, in-hospital treatments, and outcomes of the 662 504 patients used to develop the model (derivation cohort) and 284 508 used to test the model (validation cohort) are shown in Table 1 . There were no statistically or clinically significant differences in baseline demographics, comorbidities, treatment, or outcomes between the derivation and validation cohorts. The mean age was 64.8AE12.2 years and 67% were men. More than 80% had a history of hypertension and hyperlipidemia, with 28% either currently smoking or having quit within the past year. Approximately 36% of patients had a history of diabetes and 30% had a history of myocardial infarction. Most patients underwent PCI for an acute coronary syndrome, either high-risk NSTEMI/unstable angina (55.3%) or immediate PCI for STEMI (15.7%).
Overall, 1.1% of patients died in the hospital with 7.1% developing AKI and 0.3% developing AKI-D. In-hospital AKI was similar in the development (7.3%, n=48 818) and validation Table 2 . Initially, 24 independent predictors for AKI and AKI-D were identified the multivariable modeling in the derivation cohort, resulting in a model c-statistics of 0.72 and 0.89, respectively. After removing 10 and 16 variables from the models, the final models included 11 multivariate predictors for AKI (c-stat 0.71; Figure 2 ) and 6 for AKI-D (c-stat 0.88; Figure 3 ). The IDI comparing the full to reduced AKI model was 0.0024 (95% CI=0.0022, 0.0028), and for dialysis it was 0.0039 (95% CI=0.0023, 0.0052), indicating little impact on using the reduced model. The 3 variables with the largest predictive ability (defined by total t-statistic) were STEMI presentation, cardiogenic shock, and baseline CKD. Calibration was confirmed with observed versus predicted plots (Figure 4 ) and the slopes for the AKI and AKI-D predicted versus observed outcomes were 1.001 and 0.99, respectively. The discrimination and calibration in different clinical subsets is shown in Table 3 . To create simplified scores for bedside calculation, each variable in each reduced model was then assigned a weighted-integer coefficient value. The scoring system for AKI and AKI-D is provided in Table 4 . The IDI for comparing the integer and the full AKI risk model was 0.0067 (95% CI=0.006, 0.007), suggesting a small loss in predictive accuracy. The IDI for the integer model AKI-D, as compared with the full model predicting AKI-D, was 0.005 (95% CI=0.001, 0.01). Figures 5   and 6 
Comment
AKI is the most common non-cardiac complication of PCI, occurring in 1 of every 13 to 14 patients treated. By using the largest available registry of PCI patients, we developed and validated a suite of risk models to predict AKI and AKI-D in patients undergoing PCI. While the full model is most accurate and appropriate for benchmarking across hospitals, the reduced AKI model included only 11 pre-procedural variables and the AKI-D model only 6, rendering them feasible for prospective risk estimation in routine clinical care. We also created a simple integer scoring system for both models to further simplify bedside application, although there was a modest loss in discrimination. These models have the opportunity to both support quality assessment by fairly comparing the AKI rates of hospitals after adjusting for the characteristics of the patients that they treat, but also for supporting personalized medicine and quality improvement by using patient-level risk prediction to guide PCI treatment strategies, such as limiting contrast exposure, more aggressive hydration protocols, avoiding multivessel PCI in a single setting, or avoiding left ventriculograms in high-risk patients.
AKI is a serious complication of PCI and is associated with an increased risk of myocardial infarction, dialysis, length of stay, 28, 29 healthcare costs, and death. 28, [30] [31] [32] [33] Previous risk models of AKI post-PCI, while important contributions at the time, have had limited use in clinical practice. Much of the work was based upon multiple and competing clinical definitions of AKI that varied from an increase in creatinine of 25% to 2 mg/dL, which have led to wide variations in reported AKI rates from 0.7% to 19%. 2, 32, 34 Also, these studies predated the contemporary use of hydration protocols and iso-osmolar contrast agents, as recommended by societal guidelines and may not reflect contemporary rates of AKI. 32 Moreover, we have already demonstrated that even Stage 1 AKI, as defined by the AKIN criteria, is associated with increased mortality and bleeding, underscoring the value and importance of using the AKIN criteria. 37 Other AKI prediction models have also suffered by the inclusion of intra-procedural variables, such as contrast dose, which relate more to the skill and quality of decision making by the physician, rather than the inherent risk of the patient. 1, 10 These models predict patient risk following the procedure and cannot be used for tailoring preventative protocols to patients as a function of their risk, nor can they be used to provide patient-specific estimates of risk for AKI or dialysis during the informed consent process. Also, few models incorporate the entire spectrum of patients undergoing PCI. Physicians wishing to apply these historical models in routine practice need to be aware that there may be different risk scores for different types of patient undergoing PCI. In the NCDR CathPCI model, we were able to demonstrate that diagnostic prediction for inhospital AKI or AKI-D, regardless of whether the patient presents with STEMI, NSTEMI, or UA, enabling simpler implementation of a single model to accurately, prospectively estimate the risk of AKI for all patients presenting to the cardiac catheterization laboratory. The prospective use of other peri-procedural risk models, such as the NCDR bleeding model, have been associated with improved safety and outcomes. 19 Whether the use of the current model can improve AKI rates needs to be prospectively tested. Given the challenge by the Institute of Medicine to provide safer, more patient-centered care, informing patients and clinicians of patients' personalized risks for PCI is an important step to achieving better healthcare.
11 Most recently, NCDR models to predict the patient's risk of mortality, bleeding, and target vessel revascularization were used to produce a customized informed-consent form to Figure 5 . NCDR Prediction score card for acute kidney injury following PCI in a sample patient. AKI indicates acute kidney injury; CEA, carotid endarterectomy; CHF, chronic heart failure; eGFR, estimated glomerular filtration rate; HF, heart failure; IABP, intra-aortic balloon pump; NCDR, National Cardiovascular Data Registry; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention. better inform patients of treatment options and risks. 14 This was compared with usual care and recently assessed in a 9-center survey of patient experiences. Patients who received the personalized informed consent, based on their own unique pre-procedural characteristics, showed a significantly greater level of "knowledge transfer" and better understanding of procedural risks. Given that kidney injury and dialysis are common complications of PCI and the variability of risk from patient to patient, vague estimations of risk based on population-wide data or experience or intuition can be a disservice. Adding patient-specific estimates of AKI and dialysis risk, derived from the validated preprocedural multivariable models into individualized PCI consent documents can be a significant advance in the consent process for those who are about to undergo PCI. Certain potential limitations should be considered when interpreting the findings of this study. First, patients and hospitals participating in NCDR may not be representative of all US practices. However, the CathPCI registry represents >1000 hospitals across the United States and captures the majority of PCIs nationally. Second, we used the in-hospital pre-procedure creatinine as the baseline value, which may not have represented the patient's true baseline serum creatinine, and did not have access to urine output, which is also a component of the AKIN definitions of AKI. This latter omission may have failed to recognize AKI in those with reduced urine output but no increase in creatinine. Such a bias may also have been introduced in patients whose creatinine rose after discharge but was not increased by >0.3 mg/dL prior to discharge. Nevertheless, the pre-procedural and post-discharge creatinines are what is most commonly available in clinical care and markedly improve feasibility of this model in routine quality assessment. Third, we did not have data on intravenous administration of fluid, concomitant use of renal toxic medications or potentially renal protective medications, all of which may have improved model performance. Importantly, we did not include procedural characteristics, such as the use of left ventriculograms or contrast volume to predict AKI outcomes. While these would have certainly improved the c-statistics of the models, they are under the locus of control of the physician and are actionable opportunities to improve care.
Conclusions
We developed a valid and robust tool for predicting AKI and AKI-D in patients undergoing PCI. Use of these models for national quality improvement efforts, personalizing the education of patients about the risks of treatment and to adjust the technical approach to PCI may all lead to safer, higherquality care and should be tested in prospective studies. 
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